Insider transaction details
Vir Biotechnology (NASDAQ:VIR) Chief Executive Officer Marianne De Backer sold 72,559 shares of the companys common stock on April 6, 2026, for approximately $664,350. The shares were disposed of at $9.156 apiece, according to the transaction record.
Post-sale holdings and structure
Following the sale, De Backer directly holds 948,145 shares of Vir Biotechnology common stock. In addition, she has an indirect stake of 53,118 shares held through the Ureel-De Backer Family Trust, for which she and her spouse serve as trustees.
Reason for the trade
The sale was carried out automatically and mandatorily under a pre-arranged Rule 10b5-1 trading plan. The transaction was intended to cover the companys tax withholding obligations associated with the vesting of restricted stock units (RSUs).
Recent capital markets activity
In a separate development, Vir Biotechnology completed a public offering of common stock that generated roughly $172.5 million in gross proceeds. The offering comprised 20,294,117 shares sold at a public offering price of $8.50 per share. The total included an additional 2,647,058 shares that underwriters purchased by exercising a 30-day option.
The offering price of $8.50 represented a 15% discount to the prior dayrsquo;s closing price, and the announcement was followed by a 16% decline in Virrsquo;s share price.
Strategic collaboration and analyst responses
The capital raise and corporate developments came after Vir announced a strategic collaboration with Astellas Pharma to co-develop and co-commercialize VIR-5500, a PSMA-targeted T cell engager aimed at treating metastatic prostate cancer. Following that announcement and Phase 1 data for VIR-5500, a pair of analysts updated their outlooks.
H.C. Wainwright raised its price target on Vir to $20 from $15 while maintaining a Buy rating. Leerink Partners increased its price target to $20 from $16, maintained an Outperform rating, and adjusted its financial model referencing the Phase 1 data for VIR-5500 and the recent capital raise.
Company view on proceeds
While the offering price was below the previous close and the stock experienced a single-day decline, the proceeds from the offering are expected by the company to support its strategic initiatives and partnerships.
Context and performance
Virrsquo;s stock has delivered a 64% return over the past year, a performance metric noted alongside the insider sale and the recent financing activity.